Repligen Corporation

298 articles about Repligen Corporation

• Repligen Corporation to Present at the Lazard Capital Markets 7th Annual Healthcare Conference

  11/10/2010

• Repligen Corporation Reports Second Quarter Fiscal Year 2011 Financial Results

  11/2/2010

• Repligen Corporation Announces Conference Call of Second Quarter Fiscal Year 2011 Results Tuesday, November 2nd, 3:00 p.m. EDT

  10/25/2010

• Repligen Corporation Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression

  9/30/2010

• Repligen Corporation to Present at the Rodman & Renshaw Annual Global Investment Conference

  8/31/2010

• Repligen Corporation Reports First Quarter Fiscal Year 2011 Financial Results

  8/5/2010

• Repligen Corporation Receives Additional Research Grants to Support Development of HDAC Inhibitors for Friedreich's Ataxia and Huntington's Disease

  8/2/2010

• Repligen Corporation Announces Conference Call of First Quarter Fiscal Year 2011 Results

  7/27/2010

• Repligen Corporation Reports Fourth Quarter and Fiscal Year 2010 Financial Results

  6/9/2010

• Repligen Corporation Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results

  6/2/2010

• FDA, European Medicines Evaluation Agency to Re-analyze Repligen Corporation's Late-Stage Data

  5/27/2010

• Repligen Corporation Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia

  5/24/2010

• Repligen Corporation Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreich's Ataxia

  5/13/2010

• Repligen Corporation Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder

  4/30/2010

• Repligen Corporation Expects Losses In 2010, 2011

  4/16/2010

• Repligen Corporation Announces Acquisition of Chromatography Technology Platform

  3/3/2010

• Repligen Corporation Reports Third Quarter Fiscal Year 2010 Financial Results

  2/4/2010

• Repligen Corporation Announces Conference Call of Third Quarter Fiscal Year 2010 Results Thursday, February 4th, 10:00 a.m. EST

  1/29/2010

• Repligen Corporation Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A

  1/28/2010

• Repligen Corporation Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program

  12/15/2009